Kuros Biosciences Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chris Fair

Chief executive officer

CHF1.3m

Total compensation

CEO salary percentage24.6%
CEO tenureless than a year
CEO ownershipn/a
Management average tenureless than a year
Board average tenure5.6yrs

Recent management updates

Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now

Apr 12
Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now

What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay

Nov 17
What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay

Recent updates

Some Confidence Is Lacking In Kuros Biosciences AG (VTX:KURN) As Shares Slide 29%

Jan 03
Some Confidence Is Lacking In Kuros Biosciences AG (VTX:KURN) As Shares Slide 29%

Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth

Dec 17
Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth

We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth

Sep 17
We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth

Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues

Jun 28
Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues

Here's Why We're Not At All Concerned With Kuros Biosciences' (VTX:KURN) Cash Burn Situation

May 03
Here's Why We're Not At All Concerned With Kuros Biosciences' (VTX:KURN) Cash Burn Situation

Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth

Jun 11
Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth

Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now

Apr 12
Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now

Reflecting on Kuros Biosciences' (VTX:KURN) Share Price Returns Over The Last Five Years

Mar 02
Reflecting on Kuros Biosciences' (VTX:KURN) Share Price Returns Over The Last Five Years

What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay

Nov 17
What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay

CEO Compensation Analysis

How has Chris Fair's remuneration changed compared to Kuros Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023CHF1mCHF329k

-CHF14m

Sep 30 2023n/an/a

-CHF15m

Jun 30 2023n/an/a

-CHF16m

Mar 31 2023n/an/a

-CHF15m

Dec 31 2022CHF36kn/a

-CHF15m

Sep 30 2022n/an/a

-CHF13m

Jun 30 2022n/an/a

-CHF11m

Mar 31 2022n/an/a

-CHF9m

Dec 31 2021CHF36kn/a

-CHF8m

Compensation vs Market: Chris's total compensation ($USD1.49M) is above average for companies of similar size in the Swiss market ($USD924.15K).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.


CEO

Chris Fair (53 yo)

less than a year

Tenure

CHF1,337,700

Compensation

Mr. Christopher T. Fair, also known as Chris, serves as the Chief Executive Officer At Kuros Biosciences AG since October 2023. He was the Chief Operating Officer at Kuros Biosciences AG since October 03,...


Leadership Team

NamePositionTenureCompensationOwnership
Christopher Fair
Chief Executive Officerless than a yearCHF1.34mno data
Daniel Geiger
Chief Financial Officerless than a yearno datano data
Sjoerd Musters
COO & GM of BVless than a yearno datano data
Joost de Bruijn
President of Innovation and Strategy & Executive Directorless than a yearCHF873.70k0%
CHF 0
Philippe Saudan
Chief Development Officer7.6yrsno datano data
John Griffin
Chief Commercial Officer5.9yrsno datano data
Katherine Sage
Senior Vice President of Medical and Clinical Affairsless than a yearno datano data
Virginia Jamieson
Consultant5.8yrsno datano data

0.6yrs

Average Tenure

54.5yo

Average Age

Experienced Management: KURN's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Joost de Bruijn
President of Innovation and Strategy & Executive Director5.8yrsCHF873.70k0%
CHF 0
Clemens van Blitterswijk
Chairman6.8yrsCHF92.60k1.98%
CHF 3.7m
Oliver Walker
Independent Non-Executive Director5.8yrsCHF73.80kno data
Scott Bruder
Independent Non-Executive Director5.8yrsCHF86.30kno data
Cato Laurentin
Member of Advisory Boardno datano datano data
Ralph Müller
Member of Advisory Boardno datano datano data
Norbert Boos
Member of Advisory Boardno datano datano data
Thomas Steffen
Member of Advisory Boardno datano datano data
Andrew Sama
Member of Strategic Advisory Board5.5yrsno datano data
Richard Allen
Member of Strategic Advisory Board5.5yrsno datano data
Alpesh Patel
Member of Strategic Advisory Board5.5yrsno datano data
Kornelis Poelstra
Member of Strategic Advisory Board5.5yrsno datano data

5.6yrs

Average Tenure

59yo

Average Age

Experienced Board: KURN's board of directors are considered experienced (5.6 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.